Equitable Access to Rare Disease Therapies Workshop
Thursday, May 23, 2019 | 8:00 AM – 12:00 PM ET
Squire Patton Boggs | 2550 M Street, NW | Washington, DC 20037
About the Workshop
With just 5% of the over 7,000 rare diseases addressed by some form of drug treatment, 95% of rare diseases remain without a therapeutic option. Rare diseases affect 1 in 10 Americans, yet many of these debilitating conditions impact a very small number of patients. The biopharmaceutical industry is delivering tremendous innovation, from disease-modifying medications to curative gene therapies, to address previously unmet medical needs. It is imperative that these innovations be accessible to those who deserve them. This workshop brings together patients, families, patient advocacy groups, biopharmaceutical firms, providers, policymakers, and other NGOs to discuss how to achieve equitable access to care for rare diseases. Topics will include current barriers to care, ensuring earlier access, and drug pricing. Our goal is to empower patients and families who are affected by rare diseases.
Organization represented included: Alnylam Pharmaceuticals, American Autoimmune Related Diseases Association, American Telemedicine Association, AmerisourceBergen, AstraZeneca, Barth Syndrome Foundation, Birmingham VA Medical Center, Boston Scientific, Cardinal Health, Daiichi Sankyo, EveryLife Foundation for Rare Diseases, GE Healthcare, Georgetown University School of Medicine, GSK, Haystack Project: Voices of Ultra Rare, Horizon Pharma, Immune Deficiency Foundation, Ipsen, Janssen Pharmaceuticals, Johns Hopkins University School of Medicine, Medicaid Health Plans of America, Medicines for All Institute, MedImmune, National Alliance for Caregiving, National Center for Advancing Translational Sciences, National Human Genome Research Institute, National Infusion Center Association, Novartis, Organization for Rare Diseases India, Osteogenesis Imperfecta Foundation, Partnership to Fight Chronic Disease, Pfizer, Project HOPE, Rare Access Action Project, Regeneron Pharmaceuticals, RWJBarnabas Health, Sanofi, Shire, Takeda, The ALS Association, The Myositis Association, Triple Negative Breast Cancer Foundation, Vitrisa Therapeutics, and WebMD.
LEARN how rare diseases impact millions of Americans and how new therapies are developed
UNDERSTAND the major barriers to care for rare diseases
DISCUSS the complexities of drug pricing and why drug pricing has become such a crucial issue
FOCUS on how to empower patients and families who are affected by rare diseases
NETWORK with other patients, families, patient advocacy groups, biopharmaceutical firms, providers, policymakers, and NGOs
Distinguished Keynote Address
Dr. Summar is well-known for his pioneering work in caring for children diagnosed with rare diseases. He joined Children’s National in 2010 where he leads the Division of Genetics and Metabolism. He founded and Directs the Rare Disease Institute in 2017, the first dedicated home for the clinical care of patients with genetic rare diseases and The National Organization for Rare Disorders first designated Rare Disease Clinical Center of Excellence. Dr. Summar’s laboratory works on both devices and treatments for patients with genetic rare conditions and adapting knowledge from rare diseases to mainstream medicine. His work has resulted in new drugs in FDA clinical trials for patients with congenital heart disease and premature birth. He has over 30 patents and patent applications. His laboratory is best known for its work in the rare diseases affecting nitrogen, ammonia, and amino acid metabolism. Dr. Summar has also organized and led a number of international work groups to develop and publish standards of care and treatment for rare diseases resulting in significant improvements in outcomes. He has built remote/telemedicine programs to reach patients currently without genetic care access. Dr. Summar is board-certified in Pediatrics, Clinical Genetics, and Biochemical Genetics and has been listed with Best Doctor’s in America since 2004. He serves as President of the Board of Directors of the National Organization for Rare Disorders and is the past president of the Society for Inherited Metabolic Disorders. At NORD he is spearheading an effort that has created digital registries for families to collect long-term information about poorly understood diseases. He is very active in newborn screening policy issues and in developing testing and follow-up systems.
Distinguished Welcoming Address
Dr. Sherman serves as Chief Medical Officer and Executive Vice President at Horizon Therapeutics, and has more than 25 years of pharmaceutical industry experience. He also serves as an Adjunct Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine, as a member of numerous professional societies, and as a Diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. A former DIA President and member of the DIA Board of Directors, Dr. Sherman was also the 2008 DIA Annual Meeting Chair, received the DIA Outstanding Service Award, is an inaugural Fellow of DIA, and serves as the DIA liaison to the US Food and Drug Administration’s Clinical Trial Transformation Initiative Steering Committee.
Opening Remarks & Next Steps
Julius Pryor helps companies leverage Diversity & Inclusion to accelerate innovation and drive business results. He’s held executive roles at Johnson & Johnson (J&J), Coca-Cola Enterprises (CCE), Russell Athletic, Abbott Labs and Takeda Pharmaceuticals. He was Vice President of Global Diversity at both J&J and Coke. Most recently, Julius served as Head of Innovation, Diversity & Inclusion at biotech leader Genentech. Julius combines a unique vision for the future of D&I, a strong grounding in sales and management, and insights into what works across different industries and sectors. Julius saw the power of diversity to accomplish results during his 26 years of service in the U.S. Navy. He is a U.S. Navy Captain, Surface Warfare Officer and Instructor for the Navy Officer Leadership Development Program. He’s held numerous Navy leadership roles including, Unit Commanding Officer and Fleet Staff Officer. He had the honor of serving on the re-commissioning crew of the historic USS Missouri (BB-63). Julius graduated from Morehouse College and The Williston Northampton School (Easthampton, MA). He sits on the boards of the Andrew Young Center for Global Leadership and the Center for Healthcare Innovation. He is a member of the Omega Psi Phi Fraternity, having pledged at the legendary Psi Chapter at Morehouse College. Julius is the author of Thriving in a Disruptive World: 6 Critical Concepts for Navigating the 21st Century.
John Wyand, the Healthcare Public Policy Practice leader and Life Sciences Industry Group leader for the Americas, is an experienced healthcare and life sciences lawyer who focuses his practice on advising healthcare companies and providers on legal and regulatory issues. Additionally, he works to guide government healthcare policy on behalf of clients, including federal budget appropriations and regulations issues related to Medicare/Medicaid reimbursement, health information technology, health data privacy and security, and patient safety and quality improvement initiatives. He also represents hospitals and other direct-care providers in a wide range of strategic, regulatory and transactional matters. John is an M.B.A. with more than 20 years’ prior experience as a senior executive with a number of healthcare systems.
John contributes to publications on healthcare compliance issues, including fraud and abuse, and the Health Insurance Portability and Accountability Act (HIPAA) privacy and security regulations, as well as on the deployment and meaningful use of certified electronic health records.
He is a Fellow of the American College of Healthcare Executives, a member of the American Bar Association and its Ehealth, Privacy & Security Committee, the American Health Lawyers Association and the District of Columbia Bar Association and its Health Law Section.
Distinguished Speakers and Panelists
Registration, Breakfast, & Networking
Opening Remarks: Julius Pryor III, Chair of the Board of Directors at CHI
Distinguished Welcoming Address: Dr. Jeffrey Sherman, MD, Chief Medical Officer at Horizon Therapeutics
Panel Discussion: Industry Perspectives
Panel Discussion: Provider Perspectives
Distinguished Keynote Address: Dr. Marshall Summar, MD, Chairman of the Board of National Organization for Rare Disorders
Panel Discussion: Patient Perspectives
Closing Remarks: John Wyand, Senior Partner, Squire Patton Boggs
Next Steps: Julius Pryor III, Chair of the Board of Directors at CHI